Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active F...

Descripción completa

Detalles Bibliográficos
Autores principales: Henes, Joerg C., Saur, Sebastian, Kofler, David M., Kedor, Claudia, Meisner, Christoph, Schuett, Marion, Krusche, Martin, Koetter, Ina, Xenitidis, Theodoros, Schulze-Koops, Hendrik, Feist, Eugen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500594/
https://www.ncbi.nlm.nih.gov/pubmed/36143006
http://dx.doi.org/10.3390/jcm11185360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500594/
https://www.ncbi.nlm.nih.gov/pubmed/36143006
http://dx.doi.org/10.3390/jcm11185360

Ejemplares similares